NCT06540729View on ClinicalTrials.gov

RC48 in Combination With AK104 and Bevacizumab in OCCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2030

Conditions
Ovary Cancer
Interventions
DRUG

Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer

Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer

Trial Locations (1)

510120

RECRUITING

Sun Yat-sen Memorial Hospital, Guanzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER